Similar articles

• [Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].

  Wander HE, Kleeberg UR, Essers U, Blossey HC, Nagel GA. Wander HE, et al. Onkologie. 1987 Oct;10(5):321-3. doi: 10.1159/000216433. Onkologie. 1987. PMID: 2960938 Clinical Trial. German. No abstract available.
• Breast cancer: metastatic.

  Johnston S, Stebbing J. Johnston S, et al. Clin Evid. 2002 Jun;(7):1579-602. Clin Evid. 2002. Update in: Clin Evid. 2002 Dec;(8):1785-810. PMID: 12230774 Updated. Review. No abstract available.
• On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.

  Petru E, Schmähl D. Petru E, et al. Klin Wochenschr. 1987 Oct 15;65(20):959-66. doi: 10.1007/BF01717830. Klin Wochenschr. 1987. PMID: 2963170
• [Medical treatment of the breast].

  Battelli T, Manocchi P, Guistini L, Mattioli R, Ginnetti A. Battelli T, et al. Minerva Med. 1984 Feb 18;75(6):227-33. Minerva Med. 1984. PMID: 6231491 Italian. No abstract available.
• Breast cancer: metastatic.

  Johnston S, Stebbing J. Johnston S, et al. Clin Evid. 2002 Dec;(8):1785-810. Clin Evid. 2002. Update in: Clin Evid. 2003 Dec;(10):1975-2002. PMID: 12603970 Updated. Review. No abstract available.